Your browser doesn't support javascript.
loading
Schizophrenia: etiology and pharmacotherapy.
Mohammadi, M R; Akhondzadeh, S.
Afiliação
  • Mohammadi MR; Tehran University medical Sciences, Iran.
IDrugs ; 4(10): 1167-72, 2001 Oct.
Article em En | MEDLINE | ID: mdl-15957086
Schizophrenia is one of the major psychiatric disorders. Psychosis, in its narrow definition, is restricted to delusions or hallucinations in the absence of insight into their pathological nature. Impairment in psychosocial function is an essential feature of schizophrenia. Research in the last decade has confirmed that schizophrenia is a brain disorder that cannot be attributed solely to psychosocial factors. It is widely accepted from twin and adoption studies that schizophrenia has a significant genetic component. In addition, it is a general belief that schizophrenia is caused by a biological abnormality, even though all attempts to identify that abnormality have been unsuccessful. A major landmark in the history of the understanding and treatment of schizophrenia was the discovery that dopamine D2-blocking agents can control the hallucinations and delusions of schizophrenic patients. However, clinicians have noticed that classical antipsychotics are generally ineffective against the negative symptoms that are prominent in patients with a chronic course. In this article, we will focus on the etiology and pharmacotherapy of schizophrenia.
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies Idioma: En Revista: IDrugs Assunto da revista: FARMACOLOGIA Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Irã País de publicação: Reino Unido
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies Idioma: En Revista: IDrugs Assunto da revista: FARMACOLOGIA Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Irã País de publicação: Reino Unido